Department of Cardiology, Affiliated Hospital of Guilin Medical University, 15#, Lequn Road, Guilin, 541001, Guangxi, China.
Sci Rep. 2022 Feb 28;12(1):3294. doi: 10.1038/s41598-022-06923-z.
MALAT1 was reported to sponge miR-30e, miR-126 and miR-155 in the pathogenesis of many diseases. Plasma miR-30e can indicate the risk of no-reflow during primary percutaneous coronary intervention (pPCI), while miR-126 can be used as a predictor of coronary slow flow phenomenon. In this study, we compared the diagnostic value of above genes in the prediction of no-reflow phenomenon in ST-segment elevation myocardial infarction (STEMI) subjects receiving pPCI. Quantitative real-time PCR, ELISA, Western blot and luciferase assays were performed to explore the regulatory relationship of MALAT1/miR-30e, MALAT1/miR-126, MALAT1/miR-155, miR-126/HPSE, and miR-155/EDN1. ROC analysis was carried out to evaluate the potential value of MALAT1, miRNAs and target genes in differentiating normal reflow and no-reflow in STEMI patients receiving pPCI. Elevated MALAT1, CRP, HPSE, and EDN1 expression and suppressed miR-30e, miR-155 and miR-126 expression was found in the plasma of STEMI patients receiving pPCI who were diagnosed with no-reflow phenomenon. ROC analysis showed that the expression of MALAT1, miR-30e, miR-126 and CRP could be used as predictive biomarkers to differentiate normal reflow and no-reflow in STEMI patients receiving pPCI. MALAT1 was found to suppress the expression of miR-30e, miR-126 and miR-155, and HPSE and EDN1 were respectively targeted by miR-126 and miR-155. This study demonstrated that MALAT1 could respectively sponge the expression of miR-30e, miR-126 and miR-155. And miR-30e, miR-126 and miR-155 respectively targeted CRP, HPSE and EDN1 negatively. Moreover, MALAT1 could function as an effective biomarker of no-reflow phenomenon in STEMI patients receiving pPCI.
MALAT1 被报道在许多疾病的发病机制中作为 miR-30e、miR-126 和 miR-155 的海绵体。血浆 miR-30e 可指示经皮冠状动脉介入治疗（pPCI）期间无复流的风险，而 miR-126 可用作冠状动脉慢血流现象的预测因子。在这项研究中，我们比较了这些基因在预测接受 pPCI 的 ST 段抬高型心肌梗死（STEMI）患者无复流现象中的诊断价值。进行了定量实时 PCR、ELISA、Western blot 和荧光素酶测定，以探讨 MALAT1/miR-30e、MALAT1/miR-126、MALAT1/miR-155、miR-126/HPSE 和 miR-155/EDN1 的调节关系。进行 ROC 分析以评估 MALAT1、miRNAs 和靶基因在区分接受 pPCI 的 STEMI 患者正常再灌注和无复流中的潜在价值。发现在接受 pPCI 并被诊断为无复流现象的 STEMI 患者的血浆中，MALAT1、CRP、HPSE 和 EDN1 的表达升高，miR-30e、miR-155 和 miR-126 的表达受到抑制。ROC 分析表明，MALAT1、miR-30e、miR-126 和 CRP 的表达可作为预测生物标志物，用于区分接受 pPCI 的 STEMI 患者的正常再灌注和无复流。发现 MALAT1 抑制 miR-30e、miR-126 和 miR-155 的表达，而 HPSE 和 EDN1 分别被 miR-126 和 miR-155 靶向。本研究表明，MALAT1 可以分别作为 miR-30e、miR-126 和 miR-155 的海绵体。并且 miR-30e、miR-126 和 miR-155 分别负向靶向 CRP、HPSE 和 EDN1。此外，MALAT1 可作为接受 pPCI 的 STEMI 患者无复流现象的有效生物标志物。
